Source Search Page

onclive.com > view

ASCO Updates Advanced HCC Treatment Guideline

...Gordan, MD, PhD The American Society of Clinical Oncology (ASCO)... ...and Child-Pugh class A disease and an ECOG performance status of... ...Rose, MD, a professor at Yale School of Medicine in New Haven, Connecticut... ..., and the director of the Veterans Affairs Comprehensive Cancer Center...

onclive.com > view

Immunogenomics Demonstrate Predictive Capability to Immunotherapy Resistance in Uveal Melanoma

...melanoma, according to findings from a study published in Nature Communications... ...and to tumor susceptibility to the therapeutic class in patients... ..., of the Solid Tumor Cellular Immunotherapy Program, UPMC Hillman... ...Institute and UPMC Hillman Cancer Center....

onclive.com > view

The Road Beyond Frontline CDK4/6 Inhibitors in HR+/HER2– Metastatic Breast Cancer Examines Combinations...

...Erin Frances Cobain, MD, highlights the current role of endocrine... ...Erin Frances Cobain, MD Selecting optimal second- and third-line... ...Clinical Research Team at the University of Michigan Rogel Cancer... ...Cobain is an assistant professor and codirector of the Breast Cancer...

onclive.com > view

Dr Kopetz on the Future Utility of Adagrasib/Cetuximab in KRAS G12C–Mutant CRC

..., The University of Texas MD Anderson Cancer Center, discusses the... ...Scott Kopetz, MD, PhD, FACP, professor, deputy chair, Translational... ...Cranbury, NJ 08512... ...Mitigate CRS Following Axi-Cel Administration in Lymphoma 2 Commerce Drive...

onclive.com > view

Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC

...Yuankai Shi, MD, PhD Glecirasib (JAB-21822) monotherapy elicited... ...cancer (NSCLC) harboring KRAS G12C mutations, according to data... ..., AstraZeneca, BioAtla, Bristol Myers Squibb, Daiichi Sankyo, Genentech... ...Dana-Farber Cancer Institute, and an assistant professor of medicine...

onclive.com > view

Patient Factors, Toxicities Key to Selecting NALIRIFOX or Other Chemo Options in Advanced Pancreatic Cancer...

...Kian-Huat Lim, MD, PhD With the addition of NALIRIFOX (irinotecan... ...Kian-Huat Lim, MD, PhD, discusses the current treatment landscape... ...Gastric/GEJ Cancer Health Canada Green Lights Subcutaneous Atezolizumab... ...the Washington University School of Medicine in Missouri....

onclive.com > view

Expansion of Luspatercept Indication Underscores Evolving Treatment Landscape for Low-Risk MDS

...patients, such as those without SF3B1 mutations, according to Benjamin Tomlinson... ..., MD.... ...Hospitals, Cleveland Medical Center, and an assistant professor... ...prior to the 2022 World Health Organization and International Consensus...

onclive.com > view

Examining Potential Markers of Osteosarcoma Stem Cells Is at the Forefront of Research

...In the 20-specimen University of California (UC) Davis Health retrospective... ...Lor Randall, MD, FACS, discusses research examining ALDH1A1 and CD44... ...a professor at UC Davis Comprehensive Cancer Center in Sacramento... ...In the interview, Randall, the David Linn Endowed Chair for Orthopedic...

onclive.com > view

Dr Diaz on the Evolution of Precision Medicine in Cervical Cancer

...Surgery, Baptist Health; director, Ambulatory Surgery Center, Baptist... ...John Paul Diaz, MD, chief, Gynecologic Oncology; director, Robotic... ...Cranbury, NJ 08512... ...Mitigate CRS Following Axi-Cel Administration in Lymphoma 2 Commerce Drive...

onclive.com > view

Dr Konecny on PROs From the MIRASOL Trial in Advanced Ovarian Cancer